0.8616
price up icon7.04%   0.0567
after-market Dopo l'orario di chiusura: .87 0.0084 +0.97%
loading
Precedente Chiudi:
$0.8049
Aprire:
$0.8
Volume 24 ore:
4.95M
Relative Volume:
0.74
Capitalizzazione di mercato:
$53.41M
Reddito:
-
Utile/perdita netta:
$-22.83M
Rapporto P/E:
-1.0906
EPS:
-0.79
Flusso di cassa netto:
$-20.87M
1 W Prestazione:
+26.71%
1M Prestazione:
+187.20%
6M Prestazione:
+14.29%
1 anno Prestazione:
-53.17%
Intervallo 1D:
Value
$0.791
$0.8701
Intervallo di 1 settimana:
Value
$0.645
$0.8701
Portata 52W:
Value
$0.2223
$2.535

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
Nome
Cognition Therapeutics Inc
Name
Telefono
412-481-2210
Name
Indirizzo
2403 SIDNEY STREET, PITTSBURGH
Name
Dipendente
25
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-08
Name
Ultimi documenti SEC
Name
CGTX's Discussions on Twitter

Confronta CGTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CGTX
Cognition Therapeutics Inc
0.8616 48.06M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-19 Aggiornamento B. Riley Securities Neutral → Buy
2024-07-30 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-11-03 Iniziato B. Riley Securities Buy
2021-11-03 Iniziato Oppenheimer Outperform

Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie

pulisher
Jul 24, 2025

Cognition Therapeutics Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Cognition Therapeutics Inc. stock priceBreakneck growth rates - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025
pulisher
Jul 21, 2025

Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan

Jul 21, 2025
pulisher
Jul 19, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire

Jul 17, 2025
pulisher
Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com

Jul 14, 2025
pulisher
Jul 12, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

Cognition Therapeutics, Inc. (CGTX) Plunges 14.29% Amid FDA Meeting Outcome - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest

Jul 11, 2025

Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):